CD274 and esophageal squamous cell carcinoma: The latest results of the phase 1b trial (NATION‐1907) in the issue of Nature Medicine, suggest that neoadjuvant anti‐programmed death ligand 1 (anti‐PD‐L1) alone may induce significantly prolonged survival outcomes in resectable oesophagal squamous cell carcinoma (ESCC).